Literature DB >> 7802646

The soluble form of Alzheimer's amyloid beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma.

A Koudinov1, E Matsubara, B Frangione, J Ghiso.   

Abstract

The amyloid fibrils of Alzheimer's neuritic plaques and cerebral blood vessels are mainly composed of aggregated forms of a 39 to 44 amino acids peptide, named amyloid beta (A beta). A similar although soluble form of A beta (sA beta) has been identified in plasma, cerebrospinal fluid and cell culture supernatants, indicating that it is produced under physiologic conditions. We report here that sA beta in normal human plasma is associated with lipoprotein particles, in particular to the HDL3 and VHDL fractions where it is complexed to ApoJ and, to a lesser extent, to ApoAI. This was assessed by immunoprecipitation experiments of purified plasma lipoproteins and lipoprotein-depleted plasma and confirmed by means of amino acid sequence analysis. Moreover, biotinylated synthetic peptide A beta 1-40 was traced in normal human plasma in in vitro experiments. As in the case of sA beta, biotinylated A beta 1-40 was specifically recovered in the HDL3 and VHDL fractions. This data together with the previous demonstration that A beta 1-40 is taken up into the brain via a specific mechanism and possibly as an A beta 1-40-ApoJ complex indicate a role for HDL3- and VHDL-containing ApoJ in the transport of the peptide in circulation and suggest their involvement in the delivery of sA beta across the blood-brain barrier.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7802646     DOI: 10.1006/bbrc.1994.2788

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  27 in total

1.  ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-beta pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis.

Authors:  Anne M Fagan; Erin Christopher; Jennie W Taylor; Maia Parsadanian; Michael Spinner; Melanie Watson; John D Fryer; Suzanne Wahrle; Kelly R Bales; Steven M Paul; David M Holtzman
Journal:  Am J Pathol       Date:  2004-10       Impact factor: 4.307

2.  Preferential interactions between ApoE-containing lipoproteins and Aβ revealed by a detection method that combines size exclusion chromatography with non-reducing gel-shift.

Authors:  Mary Jo LaDu; Gregory W Munson; Lisa Jungbauer; Godfrey S Getz; Catherine A Reardon; Leon M Tai; Chunjiang Yu
Journal:  Biochim Biophys Acta       Date:  2011-11-23

3.  Invited commentary: lipoproteins and dementia - is it the apolipoprotein A-I?

Authors:  Nikolaos Scarmeas
Journal:  Am J Epidemiol       Date:  2007-02-13       Impact factor: 4.897

4.  Reduction in amyloid A amyloid formation in apolipoprotein-E-deficient mice.

Authors:  M S Kindy; D J Rader
Journal:  Am J Pathol       Date:  1998-05       Impact factor: 4.307

5.  Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers.

Authors:  B V Zlokovic; C L Martel; E Matsubara; J G McComb; G Zheng; R T McCluskey; B Frangione; J Ghiso
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

6.  Genetic ablation of apolipoprotein A-IV accelerates Alzheimer's disease pathogenesis in a mouse model.

Authors:  Yujie Cui; Mingwei Huang; Yingbo He; Shuyan Zhang; Yongzhang Luo
Journal:  Am J Pathol       Date:  2011-03       Impact factor: 4.307

7.  CYP46 T/C polymorphism is not associated with Alzheimer's dementia in a population from Hungary.

Authors:  Anna Juhász; Agnes Rimanóczy; Krisztina Boda; Gábor Vincze; Gyozo Szlávik; Marianna Zana; Annamária Bjelik; Magdolna Pákáski; Nikoletta Bódi; András Palotás; Zoltán Janka; János Kálmán
Journal:  Neurochem Res       Date:  2005-08       Impact factor: 3.996

8.  Amyloid-beta colocalizes with apolipoprotein B in absorptive cells of the small intestine.

Authors:  Susan Galloway; Ryusuke Takechi; Menuka M S Pallebage-Gamarallage; Satvinder S Dhaliwal; John C L Mamo
Journal:  Lipids Health Dis       Date:  2009-10-22       Impact factor: 3.876

9.  High serum Abeta and vascular risk factors in first-degree relatives of Alzheimer's disease patients.

Authors:  Laila Abdullah; Cheryl Luis; Daniel Paris; Ghania Ait-ghezala; Benoit Mouzon; Elizabeth Allen; Julia Parrish; Myles A Mullan; Scott Ferguson; Marcie Wood; Fiona Crawford; Michael Mullan
Journal:  Mol Med       Date:  2009-12-08       Impact factor: 6.354

10.  Effect of apolipoprotein E genotype and diet on apolipoprotein E lipidation and amyloid peptides: randomized clinical trial.

Authors:  Angela J Hanson; Jennifer L Bayer-Carter; Pattie S Green; Thomas J Montine; Charles W Wilkinson; Laura D Baker; G Stennis Watson; Laura M Bonner; Maureen Callaghan; James B Leverenz; Elaine Tsai; Nadia Postupna; Jing Zhang; Johanna Lampe; Suzanne Craft
Journal:  JAMA Neurol       Date:  2013-08       Impact factor: 18.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.